Consequently, therapeutic strategies should be tailored according to immunological phenotype: anti-IL-31 antibodies such as lokivetmab may be optimal for pruritus-dominant phenotypes, while JAK inhibitors provide broader cytokine modulation suitable for mixed or chronic inflammatory patterns. Here, IL31 is linked to Pruritus.